Effects of Intravenous Nifekalant as a Lifesaving Drug for Severe Ventricular Tachyarrhythmias Complicating Acute Coronary Syndrome
View Full Paper
Ask AI
Bookmark
Share
Why the study?
Does intravenous nifekalant improve arrhythmia suppression in patients with severe ventricular tachyarrhythmias complicating acute coronary syndrome?
Population
41 patients with sustained ventricular tachycardia or ventricular fibrillation producing circulatory failure…
Design
Cohort
Follow-up
3 months
Authors
Discussion
Loading...
Member takes
Implication
May suppress refractory VT/VF in ACS; hypothesis-generating pending randomized trials.
Structured PICO
Does intravenous nifekalant improve arrhythmia suppression in patients with severe ventricular tachyarrhythmias complicating acute coronary syndrome?
P
Population
41 patients (29 men, 12 women; mean age 69±14 years) with sustained ventricular tachycardia or ventricular fibrillation (VT/VF) producing circulatory failure and experiencing recurrence even after direct-current (DC) shock, complicating acute coronary syndrome (ACS). Exclusions included cardiac arrest on arrival, prior antiarrhythmic drugs before transfer, renal failure (serum creatinine >2.0 mg/dl), or sustained VT not adversely affecting hemodynamics.
I
Intervention
Intravenous nifekalant (NIF) administered as a 0.2 mg/kg bolus injection followed by continuous intravenous infusion at 0.2 mg·kg⁻¹·h⁻¹ for a mean duration of 3.7±1.5 days.
O
Outcome
Complete disappearance of sustained VT/VF following administration of NIF.surrogate
Intravenous nifekalant administered as a bolus followed by a low-dose continuous infusion is highly effective and safe for suppressing severe, shock-resistant ventricular tachyarrhythmias complicating acute coronary syndrome.
Cite This Study
Yusu et al. (2009) studied this question.
Topics
View Full Paper
Ask AI
Bookmark
Share